Story · Public Health · Medicine & Biotech
STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity
1 outlet · first reported by STAT News on
Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to… (STAT News)
Coverage, in order
-
STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesityOver the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.